Tenderwize
Back to tender search

Open House Discount Agreement for Ribociclib

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Feb 28, 2027 · 195 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Ribociclib, ATC L01EF02

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

40 / 100

Complexity

30 / 100

Risk factors

Buyer may replace open-house agreements with exclusive discount contracts during the term, potentially terminating exis...

No guaranteed purchase volumes; financial benefit depends on market share and prescribing behavior.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Non-exclusive discount agreements for pharmaceutical products containing the active ingredient Ribociclib (ATC L01EF02).
  • Agreements cover the period from 01.05.2025 to 30.04.2027 (24 months maximum).
Show full summary

This is an open-house procedure by AOK Rheinland-Pfalz/Saarland for non-exclusive discount agreements on the active ingredient Ribociclib (ATC L01EF02). The agreement is for a maximum of 24 months, starting 01.05.2025, with monthly accession possibilities. It is explicitly stated as not a public procurement under EU Directive 2014/24/EU, but published for transparency. No estimated value is provided. The procedure is open to all interested pharmaceutical companies with authorized and marketable medicines in Germany. The first submission deadline for a start on 01.05.2025 is 31.03.2025; later submissions can be made monthly. The buyer may replace these open-house agreements with exclusive discount contracts during the term.

Risks

Buyer may replace open-house agreements with exclusive discount contracts during the term, potentially terminating exis...

No guaranteed purchase volumes; financial benefit depends on market share and prescribing behavior.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Medicines must be authorized and marketable in Germany.
  • Evidence of marketability via Lauer-Taxe listing or DIMDI AMIce database extracts.
  • Participation is open to all pharmaceutical companies; no selection or negotiation.

Requirements may be incomplete.

Award Criteria

Lot 1

No award criteria explicitly specified; participation is open to all eligible companies meeting the conditions.

Buyer

Lots (1)

LOT-0001

Open House Discount Agreement for Ribociclib

Non-exclusive discount agreements for Ribociclib (ATC L01EF02) under an open-house model. All interested pharmaceutical companies meeting the eligibility criteria can participate without selection. Contracts last up to 24 months, with start dates on the first of each month. The buyer may replace these with exclusive contracts during the term.

SuppliesEU fundedElectronic submission

Location

Eisenberg, Germany

Duration

Apr 2025 - Apr 2027

Category

Pharmaceutical products

Award Criteria

No award criteria explicitly specified; participation is open to all eligible companies meeting the conditions.

Deadline

Deadline Feb 28, 2027

Procurement Details

Publication date
20 Mar 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
184252-2025

Documents (1)

Similar tenders